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ABSTRACT 
 
Background — Uncoupling protein 3 (UCP3) is a member of the 
mitochondrial anion carrier super-family of proteins expressed in the 
mitochondrial inner membrane that uncouple oxygen consumption by the 
respiratory chain from ATP synthesis. UCP3 plays a role in fatty acid 
metabolism and energy homeostasis and is required to maintain high rates 
of glucose aerobic metabolism, while deficiency in UCP3 might results in 
a metabolic shift that promotes anaerobic glycolytic metabolism. In this 
study, we investigated the effects of UCP3 genetic deletion on 
18
F-
fluorodeoxyglucose (FDG) cardiac uptake by a high-resolution positron 
emission tomography (PET)/computed tomography (CT) dedicated animal 
system after permanent coronary artery ligation. 
 
Methods and Results — To test the effects of UCP3 genetic deletion in 
vivo, cardiac 18F-FDG PET/CT was performed in UCP3 knockout 
 (UCP3
-/-
) and wild-type (WT) mice one week after induction of 
myocardial infarction or sham procedure. In sham-operated mice no 
difference in left ventricular (LV) volume was detectable between WT and 
4 
UCP3
-/-
.  After myocardial infarction, LV volume was higher in both WT 
and UCP3
-/-
 compared to sham animals, with a significant interaction  
(P < 0.05) between genotype and myocardial infarction. In sham-operated 
animals no difference in FDG standardized uptake value (SUV) was 
detectable between WT (1.8 ± 0.6) and UCP3
-/-
 (1.8 ± 0.6). After 
myocardial infarction, SUV was higher in both WT (2.2 ± 0.6) and  
UCP3
-/-
 (4.0 ± 0.9) compared to sham animals, with a significant 
interaction (P < 0.005) between genotype and myocardial infarction.  
A significant relationship (r = 0.68, P < 0.001) between LV volume and 
SUV was found. 
 
Conclusions — In a mice model of permanent coronary occlusion, UCP3 
is required to maintain high rates of glucose aerobic metabolism and its 
deficiency results in a metabolic shift that favored anaerobic glycolytic 
metabolism and increased FDG uptake. 
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INTRODUCTION 
Cardiac positron emission tomography (PET) with deoxy-2[18F]fluoro-D-
glucose (18F-FDG) is a nuclear medicine technique able to give unique 
insight into biochemical changes on a molecular level, with excellent 
sensitivity and has been increasingly used for non-invasive evaluation of 
myocardial pathophysiology in small animals (1). In the last years mice 
became the animals of choice in the pre-clinical research due to their short 
life cycle, and the possibility of genetic manipulation (2).The dimension of 
mice heart, with left ventricle wall thinner than 1 mm, represents a 
challenge for imaging acquisition and analysis in these animals, requiring 
expensive equipment capable of obtaining high-resolution images and 
established expertise (3). Good promising results have been achieved with 
PET (4) and with single-photon emission computed tomography (SPECT) 
(5,6) for rats and mice. Recently our group addressed the reproducibility of 
high-resolution PET/computed tomography (CT) system by repeated 
measurements in the same animals (7), to comprehensively evaluate the 
reproducibility of 18F-FDG for non-invasive quantification of infarct size 
in mice by a high-resolution animal PET/CT system. Heart failure (HF) 
6 
represents one of the main causes of death and mortality in the Western 
countries and this pathological condition is caractherized by molecular 
changes which result in altered trascritional leveles of key enzymes and 
proteins. In particular, Uncoupling protein 3 (UCP3), a member of the 
mitochondrial anion carrier expressed in the mitochondrial inner 
membrane that uncouple oxygen consumption by the respiratory chain 
from ATP synthesis, seems to be involved in the adaptive modifications of 
the failing heart (8). Patients with heart failure also have elevated plasma 
free fatty acid (FFA) concentrations. Elevated FFA levels are associated 
with increased cardiac mitochondrial uncoupling proteins (UCPs), which, 
in turn, are associated with decreased mitochondrial respiratory coupling 
and low cardiac efficiency. UCP3 plays a role in fatty acid metabolism and 
energy homeostasis and is required to maintain high rates of glucose 
aerobic metabolism, while deficiency in UCP3 might results in a metabolic 
shift that promotes anaerobic glycolytic metabolism. In this study, we 
investigated the effects of UCP3 genetic deletion on 18F-FDG uptake by 
PET/CT dedicated animal system after the induction of myocardial 
infarction (MI) by permanent coronary artery ligation. 
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 Role of molecular imaging 
The universal definition of molecular imaging, as aprroved by tha task 
force recommended and the MICoE and SNM boards is the following:  
"Molecular imaging is the visualization, characterization, and  
measurement of biological processes at the molecular and cellular levels in 
humans and other living systems" (9).  E.A. Zerhouni, former director of 
the National Institutes of Health, has described molecular imaging as 
having “…the potential to define itself as a core interdisciplinary science 
for extracting spatially and temporally resolved biological information at 
all physical scales from Angstroms to microns to centimeters in intact 
biological systems" (10).This biomedical research discipline allows the 
early identification of biologic processes underlying pathological 
conditions at cellular and subcellular levels, before of  clinical 
manifestations. Actually many diseases are identified only after the 
appearance of symptoms. Conventional imaging techniques allows the  
diagnosis of diseases sometimes in an advanced stage; so to restrain the 
evolution of disease and to avoid the relentless progression, we need to  
recognize it in a very early stage. Molecular imaging allows the 
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identification of cellular and molecular pathways and mechanisms of 
disease present in the living subject. In this way, biologic processes can be 
studied not in vitro or ex vivo biopsy/cell culture laboratory techniques, 
but in their own physiologically  environment. Molecular imaging constis 
of  multiple image-capture techniques and can be performed with a range 
of instruments, with a specific region of the electromagnetic spectrum 
including magnetic resonance imaging (MRI), x-ray computed 
tomography (CT), positron emission tomography (PET), single photon 
emission computed tomography (SPECT), and optical (bioluminescence 
and fluorescence imaging). New imaging instruments were designed and 
fabricated with the purpose of advancing the use of small research animals 
in molecular imaging studies through the use of dedicated imaging 
instruments with high sensitivity and resolution. Moreover, dual modality, 
as hybrid PET/CT scanners, have become the refernce tool for nuclear 
medicine, and dedicated PET/CT and SPECT/CT scanners for small 
animal imaging are now used routinely. The advantages of these integrated 
instruments derives from the possibility of combining functional imaging 
strength of one technology, such as PET and SPECT, with the high 
resolution anatomical imaging afforded by MRI or CT. The various 
9 
imaging technologies differ in many aspects such as depth penetration, 
spatial resolution,  energy expended for image generation, availability of 
injectable/biocompatible molecular probes and the respective detection 
threshold of probes for a given technology. PET, in particular, is a nuclear 
medicine technique for in vivo evaluation of molecular events, 
quantification of metabolic functions in organs and tissues and it is 
currently used for diagnosis and assessment of therapy response. In the last 
decades nuclear medicine techniques are widely used also in preclinical 
field. In particular small animal PET tomographs, with an improved low 
spatial resolution (that reaches 1 mm), permit macroscopic visualization of 
cellular processes and give the possibility of longitudinally following the 
development of the disease or the response to a specific new therapy 
overtime and in the same subject reducuing the number of animals 
employed (11). Moreover preclinical PET imaging could be defined a 
"translational imaging” because of employing the same technology in an 
experimental setting and in clinical practice. MRI also is used in pre-
clinical studies, with the advantage of higher spatial resolution and the 
ability to extract physiologic and anatomic information simultaneously.  
Molecular imaging  allows to visualize, characterize and quantify normal 
10 
and pathologic processes at the cellular and subcellular level by molecular 
targets.  The choice of target is generally based on key molecules, such as 
specific cell surface markers, genes or gene products that are specifically 
associated with a particular physiologic or pathologic process.  In 
particular, genomics and proteomics have developed  techniques to 
identify genes involved in disease processes, and specific proteins that are 
structurally abnormal or that are expressed at abnormally high or low 
levels in a disease state. In the last decades, molecular imaging is a rapidly 
growing with the potential to elucidate biological processes at the cellular 
and molecular levels, and to translate scientific discoveries in the research 
laboratory into the clinical setting.  Data derived from preclinical 
assestment and their translation into clinical trials promises to accelerate 
the development of individualized therapies tailored to a patient’s genetic 
composition. Molecular imaging offers unique insights that allow a more 
personalized approach to evaluation and management of cardiovascular 
diseases, such as: ischemic injury, heart failure, and left ventricular 
remodeling; thrombosis, atherosclerosis, and vulnerable plaque; 
angiogenesis, transplant rejection, and arrhythmic substrates. 
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 Cardiovascular diseases and their pathological basis. 
Cardiovascular diseases, such as Coronary Heart Disease (CHD) represent 
a leading cause of morbidity and mortality in the western countries and a 
relevant cause of permanent disability, myocardial infarction and 
congestive heart failure (12).  Despite several progression in diagnosis and 
treatment of coronary artery diseases and myocardial ischemia,  there is a 
growing interest for the study of cardiac metabolism as a potential target 
for the treatment of cardiovascular diseases. A reduced cardiac energy 
status, which decreases the functional capacity of the myocardium, is 
associated with heart failure (13). Chronic changes in cardiac metabolism 
are supported by trascritional alterations which consist in the swicht from 
the prevalent oxidation of fatty acids to glucose oxidation. This alterated 
metabolic status is sometimes associated with changes in trascritional 
levels of different key enzymes, such as Uncoupling Protiens (UCPs), a 
family of anion carrier proteins localized at the level of the mitochondrial 
inner membrane where they plays a role in mitochondrial energy 
metabolism as well as reactive oxygen species (ROS) generation (14). 
These proteins catalyze a regulated proton leak across the mitochondrial 
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inner membrane, diverting free energy from the ATP synthesis chain to the 
production of heat (15)  and thus reducing reactive oxygen species 
production (16) (Figure 1 ). So far, 5 UCP isoforms have been identified in 
mammals, named UCP1 to 5 in order of their discovery (17). UCP1, the 
first isoform discovered, is primarily expressed in the brown adipose 
tissue, where it dissipates the energy potential generated by respiration to 
serve both thermoregulatory and metaboregulatory roles (18). UCP2 is 
present in many organs and cell types, and UCP3 is  predominantly 
expressed in skeletal muscle; different from UCP1, they do not contribute 
to adaptive thermogenesis but may be involved in the resting metabolic 
rate (19). In particular both UCP2 and UCP3 seem to be involved int the 
control of reactive oxygen species levels and  regulation of  fatty acid 
metabolism,  whereas UCP2 only seems to control insulin secretion (20) 
and UCP3 is probably involved in fatty acid metabolism in skeletal muscle 
and heart (21).  
UCP3 is also involved in regulation of fatty acid metabolism, adaptive 
responses to acute exercise and prevention of reactive oxygen species 
(ROS) formation. To address these questions, Vidal-Puig et al. have 
generated a transgenic murine model lacking UCP3 (UCP3 knockout 
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mice) and in this transgenic murine model they have found that skeletal 
muscle mitochondria are more coupled and that ROS production is 
increased (22). We know that in the failing heart there is an alterated 
metabolic state characterized, for example, by an enhanced mitochondrial 
ROS production which contributes to the alterated cardiomyocytes 
function (23,24). Under normal conditions, cardiac muscle satisfies its 
high-energy requirements by oxidizing fatty acids (FAs) and carbohydrates 
and, to a lesser extent, amino acids. The failing heart, instead,  looses its 
metabolic flexibility and relies more on glucose as its preferential 
substrate. UCP3 in particular acts as a  fatty acid anion transporter, to 
protect from lipid peroxidation (25). When fatty acid supply is high, a 
larger fraction of fatty acid enters the matrix via a transmembrane fatty 
acid flip-flop mechanism; the imported fatty acid would be 
nonmetabolized and accumulated because of the lack of matrix acyl-CoA 
synthases (26). Accumulation of fatty acid in the matrix increases the risk 
of mitochondrial lipid peroxidation, which may be toxic. UCP3-mediated 
fatty acid efflux would protect against such damage. Moreover, a positive 
correlation between fasting plasma-free-fatty acid concentrations and 
cardiac UCP3 protein levels has been found in patients suffering from 
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heart failure (21). UCP3 is also expressed in cardiac muscle, where  its 
role remains relatively unexplored and it is controversial if it plays a 
beneficial or detrimental role in heart failure development (27). Actually it 
has been suggested that under hypoxic conditions, mitochondria can 
damage cardiomyocytes generating toxic reactive oxygen species (ROS) 
and that cardiac UCP3 activation attenuates ROS production (28)  and 
related cellular damage in myocardial areas of acute or chronic ischemia 
and upon reperfusion (29). At the same time, UCP3 up-regulation could 
have a detrimental effect in heart failure progression, contributing to 
energy deficit and reduced cardiac efficiency, via uncoupling 
mitochondrial respiration (30). Animal models over- or under-expressing 
UCP3, evaluated by ex vivo genomic or proteomic analysis, did not 
provide uniform answers. Increased mitochondrial uncoupling, affecting 
total ATP synthesis rates, could be an important candidate to explain this 
decreased cardiac energy status. Given the presence of UCP3 in cardiac 
tissue, it can be postulated that an increased UCP3-mediated uncoupling 
contributes to the observed energy deficit in cardiac tissue during heart 
failure. Animal models  are currently used to understand in vivo the 
pathophysiological mechanism causing heart diseases and to improve 
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diagnosis and therapeutic strategies. At the same time, dedicated high 
resolution small animal imaging has acquired a critical role in rodent 
cardiac studies,  replacing ex vivo techniques such as histology, 
autoradiography and radiation counting of tissue samples.  Positron 
Emission Tomography (PET), in particular, is a successful tool to study 
non invasively, quantitatively and repeatedly, gene expression involved in 
myocardial energetic metabolism, apoptosis, angiogenesis, hypoxia, 
inflammation, and to measure infarct size, a relevant clinical objective for 
early monitoring the response to innovative molecular therapies. 
Nevertheless, serial assessment of morphometric changes are also relevant 
in the evaluation of  left ventricular (LV) pathophysiology. Therefore, 
assessment of  LV geometry, in addition to biochemical properties of the 
myocardium, within the same PET would be highly desiderable, because it 
obviates the need for a second imaging modality (31,32). Association with 
X-ray Computed Tomography (micro-CT) adds high resolution anatomical 
information, allowing a fine spatial localization of the radiotracer 
biodistribution.  
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AIM OF THE WORK 
In this study we used in vivo 18F-FDG PET/CT to assess myocardial 
viability, to quantify heart glucose metabolism and to measure infarct size 
in a  mouse model lacking UCP3. We also evaluated a novel method for 
the additional quantification of LV volumes and total surface area working 
on polar maps obtained by static and nongated 18F-FDG PET datasetwith 
the purpose of  evaluate potential utility of 18F-FDG PET/CT to highlight 
alterations in myocardial energetic metabolism and morphology. 
 
MATERIALS AND METHODS 
 Animal studies 
Animal experiments conformed to the “Guide for the Care and Use of 
Laboratory Animals” published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996) and were approved by the 
animal welfare regulation of University Federico II of Naples, Italy. Mice 
were purchased from the Jackson Laboratory (genetic background-strain: 
129S4/SvJae). The UCP3
-/-
 mice were obtained as previously described 
(22). Male adult UCP3
-/-
 (aged 8 to 9 weeks, n=17) and WT mice (aged 8 
17 
to 9 weeks, n=14) were included in the study and maintained under 
identical conditions of temperature (21±1°C), humidity (60±5%), and 
light–dark cycle and had free access to normal mouse chow.  
 
 Mouse model of myocardial infarction 
Myocardial infarction was induced in UCP3
-/-
 (n=8) and WT mice (n=8) 
by permanent ligation of the eft coronary artery. Sham-operated animals 
underwent the same procedure without ligation of the left coronary artery 
at the same time (sham: WT n=6 and UCP3
-/-
 n=9). Permanent ligation of 
left coronary artery was performed as previously described (33) using a 
surgical microscope to clearly detect and ligate the small vessel, dedicated 
microsurgical instruments, thin sutures and needles, and a customized 
mouse ventilator (Harvard Apparatus, March-Hugsstetten, Germany). 
Briefly,  mice were anesthetized with 2.4% sevofluorane plus oxygen, 
fixed in a supine position on a heating table to prevent hypothermia, 
intubated and ventilated with a tidal volume of 200 µl and a respiratory 
rate of about 110 breaths/min.  The toracotomy was performed by a 
trasverse 5 mm incision of the left fifth intercostal space, 2 mm away from 
the left sternal border, then the pericardial sac was opened and the left 
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anterior descending coronary artery (LAD) was occluded 2–3 mm distal to 
the tip of the left auricle using a 7.0 silk suture. 
 
 Trans-thoracic echocardiography 
Trans-thoracic echocardiography was performed 7 days (range 5-8) after 
surgery in both myocardial infarction and sham groups using the Vevo 770 
high-resolution imaging system (VisualSonics), as previously described 
(34). Briefly, mice were anesthetized with an intramuscular injection of 
ketamine 100 mg/kg and xylazine 2.5 mg/kg, and echocardiograms were 
performed with a 30-MHz RMV-707B scanning head. Cardiac function 
was evaluated by measuring LV fractional shortening. 
 
 
 Protocol for PET/CT studies 
The accuracy and reproducibility of high-resolution positron emission 
tomography/computed tomography with 2-deoxy-2 [18F]fluoro-D-glucose 
(18F-FDG) for noninvasive quantification of myocardial infarct size in 
mice have been recently documented (7). The same day of 
echocardiography,  PET/CT was performed in all mice using a dedicated 
19 
animal PET/CT scanner (dual ring version)(eXplore Vista, GE Healthcare, 
Milwaukee, WI, USA) with an axial field of view (FOV) of 4.8 cm and a 
transaxial FOV of 6.7 cm. PET radial spatial resolution was of 1.6 mm 
full-width at half maximum and a CT spatial resolution of 200 µm. 
Proprietary software permitted to perform PET/CT co-registration and 
semi-quantitative analysis of PET dataset. The animals had unrestricted 
access to water and their normal food before scanning. Prior to imaging, 
mice were warmed for 15 minutes with an infrared lamp to induce 
vasodilatation of the lateral tail vein, then anesthetized with a mixture of 
isoflurane 4% and oxygen 1 L/minute for 5 minutes and positioned in the 
mouse restrainer. A dose of 300 MBq/kg of 
18
F-FDG was administrated as 
a bolus in the lateral tail vein by a 30-gauge needle (injection volume, 100 
µl). Animals were maintained at a temperature of 23°C during the 
biodistribution of FDG. After 40 minutes, mce were anesthetized with 
ketamine 100mg/kg and xylazine 10 mg/kg (injection volume, 100 
µl/10g). Thereafter, the mice, with the heart centered in the tomograph, 
were symmetrically positioned on a warm bed with micropore tape, and a 
15-minute static PET (single bed position with an axial field-of-view of 
4.8 cm; energy window 250-700 keV) scan was performed, followed by a 
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7-minute CT scan. This standardized procedures improved animal welfare 
and heart visualization with FDG, avoiding stress for restrain or cold to 
reduce interscapular brown fat and and improve the uptake in the target 
structure.  
 
 Images analysis 
PET/CT images were processed as previously described (7). PET data 
were reconstructed using a 3D-FORE/2D-OSEM iterative algorithm (16 
subsets, 2 iterations, matrix size 175 × 175, voxel size of 0.3875 × 0.3875 
× 0.7750 mm
3
) including random, scatter correction, dead time, decay, and 
attenuation correction using CT data. Reconstructed images were 
reoriented to obtain axial sections perpendicular to the left ventricle long 
axis and the whole ventricle wall was manually segmented tracing a region 
of interest in each slice (eXplore Vista Software). FDG myocardial uptake 
was measured in the left ventricle wall volume and expressed as 
standardized uptake value (SUV): tissue activity (MBq/cc)/[injected dose 
(MBq)/body weight (g)]). Automated image analysis software 
(MunichHeart) was used to measure left ventricle volume  and infarct size 
on the basis of volumetric sampling of tracer uptake (35). This software 
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allowed long-axis definition, volumetric polar map calculation, and report 
page generation for the database. Each polar map was normalized to its 
maximum uptake value. Extent of infarct was expressed in percentage 
value (% defect area/LV area) by counting the elements in the polar map 
with an activity below a threshold (50% of the maximum) and relating this 
value to the total number of polar map elements. The reproducibility and 
accuracy of this approach for measurement of infarct size in a mice model 
of permanent coronary occlusion have been documented (7) 
 
 Histology 
Twenty mice (16 of MI group and 4 of sham group) were killed      
immediately after the PET/CT scan to perform histological analysis. 
Hearts were arrested in diastole with a 300-lL injection of saturated KCl 
solution in the right atrium and then excised. The heart was excised and 
immersed into 10% buffered formalin solution for 24 hours. After being 
kept for more than 2 days in 10% buffered formalin solution, the whole 
left ventricle was embedded in paraffin. Transverse serial sections 20-µm 
thick were cut, and every 50th section from the apex to the base (every 1 
mm) was mounted and stained with Masson’s trichrome. Between five and 
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seven slides were obtained from each heart and photographed and 
analyzed morphometrically. Calibrated and magnified digital photographs 
were analyzed planimetrically using Java-based image processing program 
(ImageJ, National Institutes of Health, Bethesda, MD). The midmyocardial 
contour of the viable LV wall and the extent of scarred myocardium were 
traced on each image. Measurements from the slides were averaged and 
infarct size was expressed as a percentage of scar tissue to total left 
ventricular area (36). 
 
 Statistical analysis 
All data were expressed as mean ± standard deviation. Comparisons 
between two groups were performed using the unpaired Student t test. 
Two-way analysis of variance was performed to analyze differences by 
genotype and myocardial infarction among the four groups, including a 
Tukey post-hoc analysis if a significant F test occurred. Linear regression 
analysis was performed to evaluate the relationship between LV volume 
and SUV. A p value <0.05 was considered statistically significant. 
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RESULTS 
Individual values of LV volume in the four groups of mice are illustrated 
in Figure 1. In sham-operated mice no difference was detectable between 
WT (56.1 ± 6.1 µl) and UCP3
-/-
 (58.7 ± 5.1 µl). After myocardial 
infarction, LV volume was higher in both WT (59.9 ± 9.3 µl) and UCP3
-/-
 
(75.5 ± 10.8 µl) compared to sham animals, with UCP3
-/-
 mice showing 
the highest values. At two-way analysis of variance a significant 
interaction (P < 0.05) between genotype and myocardial infarction was 
found (Table 1). 
At trans-thoracic echocardiography, sham-operated UCP3
-/-
 mice showed 
LV fractional shortening comparable to WT (56.5 ± 4.6% and 54.1 ± 4.2%, 
respectively, P = NS). After myocardial infarction, LV fractional 
shortening was significantly lower (p < 0.05) in both WT (42.7 ± 3.1%) 
and UCP3
-/-
 (24.4% ± 2.5%) mice compared to sham-operated animals. 
UCP3
-/-
 mice displayed a significant worsening in cardiac function after 
coronary artery ligation compared with WT (P < 0.05). Furthermore, 
UCP3 genetic deletion increased infarct size after coronary artery ligation 
as compared to WT (44 ± 9% vs. 29 ± 7%, P <0.005). Vertical long-axis, 
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horizontal long-axis, and short-axis slices and the resulting polar map in a 
WT mouse and an UCP3
-/-
 mouse after myocardial infarction are 
illustrated in Figure 2. 
Figure 3 shows individual values of SUV in the four groups of mice. In 
sham-operated animals no differences were detectable between WT (1.8 ± 
0.6) and UCP3
-/-
 (1.8 ± 0.6). After myocardial infarction, SUV was higher 
in both WT (2.2 ± 0.6) and UCP3
-/-
 (4.0 ± 0.9) compared to sham animals, 
with UCP3
-/-
 mice showing the highest values. The results of two-way 
analysis of variance are reported in Table 2. As shown, a significant 
interaction (P <0.005) between genotype and myocardial infarction was 
found. Finally, at linear regression analysis a significant relationship 
(r=0.68, P <0.001) between LV volume and SUV was found (Figure 4). 
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DISCUSSION 
In this study we investigated the role of UCP3 protein in cardiac 
remodelling and heart failure progression in wild type and UCP3
-/-
 mice 
models of myocardial infarction. We  evaluated alterations in myocardial 
energetic metabolism related to UCP3 expression by in vivo 18F-FDG 
PET imaging. Moreover, we quantified non invasively left ventricle 
geometrical parameters such as total surface area and volume by Munich 
Heart software for the first time. This study demonstrates that after 
permanent coronary artery ligation UCP3 genetic deletion is associated 
with higher cardiac FDG uptake, larger infarct size and remodeling as 
compared to WT mice. These findings suggest that UCP3 deletion induces 
a metabolic shift that favored anaerobic glycolytic metabolism. Moreover, 
the larger area of necrosis and remodeling in response to ischemia in mice 
leaking UCP3 confirms the cardioprotective role of this protein. 18F-FDG 
PET is considered a gold standard in identifying patients with coronary 
artery disease and left ventricular dysfunction (37) with the clear 
advantage to provide serial measurements over time, useful to monitor the 
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evolution of a disease or the response to a treatment. The failing 
myocardium is characterized by changes in energy and substrate 
metabolism, that could reflect an increased energy demand and/or a 
compromised capacity to generate sufficient amounts of ATP (38). Under 
normal conditions, the oxidation of fatty acids and glucose covers 
approximately 65% and 30% of cardiac energy demand, respectively. The 
significance of the metabolic shift from fatty acids towards glucose in 
failing myocardium is still being debated whether it should be considered 
adaptive or maladaptive. Various biochemical and genomic mechanisms 
have been involved in the alterations of energy metabolism in failing heart 
(30). It has been postulated that mitochondrial efficiency can be reduced 
due to the increased activity of UCPs, which may dissipate part of the 
mithocondrial proton gradient used to generate ATP. However, the exact 
biological function of UCP3 is already not clear and seems to be involved 
in mithocondrial uncoupling, export of fatty acids out of the mitochondrial 
matrix and inhibition of ROS production (39, 50) (Figure 5) . Both 
increases and decreases in UCP2 and UCP3 expression were reported in 
animals and patients with congestive heart failure (40, 41).  UCP3 was 
required to maintain high rates of glucose aerobic metabolism, while 
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deficiency in UCP3 resulted in a metabolic shift that favoured anaerobic 
glycolytic metabolism, and increased glucose uptake (42). Mouse models 
in which UCP3 is overexpressed have reduced fat stores and are resistant 
to diabetes induced by dietary modifications, while knockout are obese 
and predisposed to type 2 diabetes and show increased sensitivity to 
oxidative damage in the muscle. Currently there are limited data on the 
UCP3 activity in the heart. In basal conditions there aren't significant 
differences in the mitochondrial membrane potential between wild type 
and UCP3
-/-
. Thyroid hormones or fasting induce an increased expression 
of UCP3 in the heart (30). In patients with heart failure, the increased 
expression of UCP3 is related to a state of energy deficit infarction (21). 
The positive correlation between overexpression of UCP3 in heart failure 
and the rate of plasma non-esterified fatty acids (Free fatty acids, FFAs) 
suggests a primary role of UCP3 in the metabolism of fatty acids, similarly 
to the skeletal muscle. The increased cardiac expression of UCP3 in the 
course of heart failure would increase the transport of fatty acids across the 
mitochondrial membranes, protecting the mitochondria by the action toxic 
due to the accumulation of these anions (30). Furthermore, in case of 
ischemia and reperfusion, the mitochondria produce "reactive oxygen 
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species" (ROS) that can damage the cardiomyocytes. UCP3 is expressed in 
response to an ischemic insult, activating a mechanism cytoprotective 
antioxidant, as it is capable of reducing the production of ROS and 
subsequent reperfusion injury. Therefore, this protein is potential 
therapeutic target for the management of CHD (29). In rats it has been 
shown that the expression of UCP3 is inversely associated with infarct 
size, probably by activating a protective mechanism to prevent the death of 
cardiomyocytes in the tissue surrounding the infarcted area (43). Several 
PET clinical studies reported depressed fatty acids utilization in various 
forms of cardiomyopathy (44-47). Decreased, unchanged  and increased 
cardiac deposition of FDG has been reported in the human failing heart; 
likewise autoradiography studies in cardiac hypertrophy rat model 
revealed that the cardiac uptake of radiolabelled fatty acids analogues was 
diminished and the uptake of FDG was enhanced (48). PET FDG uptake in 
skeletal muscles confirmed this findings in UCP3
-/-
 and wild type mice 
(49). In this study we found that after permanent coronary artery ligation, 
infarct size and LV volume were significantly greater in UCP3
-/-
 group 
compared to WT mice. Infarct size is one of the major determinants of 
post-ischemic cardiac remodeling and adverse outcome. To evaluate 
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cardiac function in WT and UCP3
-/-
 mice after myocardial infarction, 
transthoracic echocardiography was performed in all experimental groups. 
Sham-operated UCP3
-/-
 mice showed LV fractional shortening comparable 
to WT. After myocardial infarction, LV fractional shortening was 
significantly lower compared to sham-operated mice in both WT and 
UCP3
-/-
 mice. Moreover, UCP3
-/-
 mice displayed a significant worsening in 
cardiac function after coronary artery ligation compared with WT. 
Mailloux et al. (49) demonstrated that deficiency in UCP3 resulted in a 
metabolic shift in skeletal muscles that favored anaerobic glycolytic 
metabolism, increased glucose uptake and increased sensitivity to 
oxidative challenge and these findings were confirmed by FDG uptake at 
PET imaging. To explore whether this metabolic shift towards glycolysis is 
present also in cardiac muscle, we measured glucose uptake by monitoring 
myocardial FDG uptake in UCP3
-/-
 and in WT mice with and without 
coronary artery ligation. Our results show no differences in sham-operated 
animals between WT and UCP3
-/-
. On the other hand, after myocardial 
infarction SUV was higher in both WT and UCP3
-/-
 compared to sham 
animals. Noteworthy, UCP3
-/-  
mice showed the highest value of SUV and 
the results of two-way analysis of variance demonstrated a significant 
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interaction between genotype and myocardial infarction. We also found a 
significant relationship between LV volume and SUV. This finding 
indicates that adverse remodeling and metabolic derangement are direct 
related and that UCP3 deletion has an unfavorable impact on both 
parameters. 
 
CONCLUSIONS 
In his study we demonstrate, for the first time that, in a mice model of 
permanent coronary occlusion, UCP3 is required to maintain high rates of 
glucose aerobic metabolism and its deficiency results in a metabolic shift 
that favored anaerobic glycolytic metabolism and increased FDG uptake. 
Moreover we found a negative remodelling of the left ventricle in response 
to ischemia in mice leaking UCP3, confirming the cardioprotective role of 
this protein. 
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Table 1: Effects of genotype and myocardial infarction and their 
interaction on left ventricular volume at two-way analysis of variance 
 
 Sum of 
square 
Degree of 
freedom 
Mean 
square 
F 
value 
P 
value 
Model 1782 3 594 8.78 0.0003 
Genotype 627 1 627 9.27 0.005 
Myocardial infarction 805 1 805 11.9 0.002 
Genotype/myocardial 
infarction 
323 1 323 4.78 0.04 
Residual 1826 27 68   
Total 3608 30 120   
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Table 2: Effects of genotype and myocardial infarction and their 
interaction on SUV at two-way analysis of variance 
 
 Sum of 
square 
Degree of 
freedom 
Mean 
square 
F 
value 
P 
value 
Model 24 3 8.0 14.4 0.0001 
Genotype 5.8 1 5.8 10.3 0.003 
Myocardial infarction 12 1 12 21.6 0.0001 
Genotype/myocardial 
infarction 
5.4 1 5.4 9.79 0.004 
Residual 15 27 0.56   
Total 39 30 1.30   
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Figure 1 
 
 
 
Individual values for LV volume in sham-operated and myocardial 
infarction WT and UCP3-/- mice. Closed circles indicate mean ± standard 
deviation. 
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Figure 2 
 
 
 
 
Vertical long-axis, horizontal long-axis, and short-axis slices (on the 
bottom) and the resulting polar map (on the top) in a WT mouse (A) and 
an UCP3-/- mouse (B) after myocardial infarction. 
45 
 
 
 
Figure 3  
 
 
 
Individual values for SUV in sham-operated and myocardial infarction WT 
and UCP3-/- mice. Closed circles indicate mean ± standard deviation. 
 
 
 
 
 
 
 
46 
 
 
Figure 4 
 
 
 
 
Relationship between LV volume and SUV at linear regression analysis. 
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Figure 5 
 
The mitochondrial proton gradient generated by complexes of respiratory 
chain is used by F0-F1-ATP synthase to phosphorylate ADP. Another 
mechanism consuming the gradient and lowering ATP synthesis is proton 
leak (yellow arrow). The reentry of protons in the matrix noncoupled with 
ATP synthesis is an energy-dissipating mechanism. The brown fat UCP1 is 
an example of mitochondrial proton leak. Cyt C, cytochrome C; H+, 
proton electrochemical gradient; e-, electron; F0: membranous part of 
ATP-synthase; F1: catalytic part of ATP-synthase. 
(Adapted from “The Biology of Mitochondrial Uncoupling Proteins” 
Rousset S. et al. Diabetes. 2004;53 Suppl 1:S130-5.)  
